ADMA Biologics (NASDAQ:ADMA) Announces Earnings Results

ADMA Biologics (NASDAQ:ADMA) issued its earnings results on Thursday. The biotechnology company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.05, Briefing.com reports. The firm had revenue of $107.20 million for the quarter, compared to the consensus estimate of $86.44 million. ADMA Biologics had a positive return on equity of 17.24% and a negative net margin of 1.29%. The business’s quarterly revenue was up 78.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.02) earnings per share. ADMA Biologics updated its FY 2024 guidance to EPS and its FY 2025 guidance to EPS.

ADMA Biologics Stock Performance

Shares of NASDAQ ADMA traded up $3.77 during trading hours on Friday, hitting $15.96. 13,326,616 shares of the company’s stock were exchanged, compared to its average volume of 2,989,646. The company’s 50-day moving average price is $11.64 and its 200-day moving average price is $8.27. The company has a debt-to-equity ratio of 0.91, a current ratio of 5.21 and a quick ratio of 1.86. The stock has a market capitalization of $3.70 billion, a price-to-earnings ratio of -804.00 and a beta of 0.55. ADMA Biologics has a 1-year low of $3.06 and a 1-year high of $16.64.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, CEO Adam S. Grossman sold 100,000 shares of the company’s stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $10.72, for a total value of $1,072,000.00. Following the completion of the transaction, the chief executive officer now owns 2,081,475 shares of the company’s stock, valued at approximately $22,313,412. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 3.70% of the company’s stock.

Analysts Set New Price Targets

ADMA has been the subject of several recent analyst reports. Raymond James upped their price target on ADMA Biologics from $8.00 to $10.00 and gave the stock a “strong-buy” rating in a research note on Friday, May 10th. Cantor Fitzgerald upped their price target on ADMA Biologics from $15.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday. HC Wainwright upped their price target on ADMA Biologics from $7.50 to $10.00 and gave the stock a “buy” rating in a research note on Friday, May 10th. Finally, Mizuho boosted their price objective on ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Thursday, June 20th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $13.50.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.